ArticleTopics in spinal cord injury rehabilitation2025
Association of Hallucinogen Use With Psychosocial Outcomes: Secondary Analysis of the Spinal Cord Injury Model Systems Database.
Article in Topics in spinal cord injury rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Individuals with spinal cord injuries (SCI) experience depression at rates up to 5 times higher than the general population. Although research on hallucinogens for treating depression is growing, no studies have specifically focused on individuals with SCI. Objectives: To identify factors associated with hallucinogen use and explore the relationship between hallucinogen use and psychosocial outcomes (i.e., depression and quality of life [QOL]) among individuals with SCI. Methods: This exploratory, retrospective cross-sectional study design used data from 9976 participants in the Spinal Cord Injury Model Systems (SCIMS) National Database (NDB) between 2016 and 2021. The study outcomes were depression (Patient Health Questionnaire-9 [PHQ-9]) and QOL (Satisfaction with Life Scale [SWLS]). Hallucinogen use, measured by the WHO ASSIST 2, was dichotomized into some use versus no use. Results: Overall, 65 participants (0.7%) reported some hallucinogen use in the prior 3 months. Multivariable logistic regression analysis showed that younger age, male sex, fall(s) in the previous year, and sleep disturbances were all associated with hallucinogen use. In multivariable linear regression, hallucinogen use was significantly associated with higher PHQ-9 scores (effect size [ES] 0.558) but was not significantly related to SWLS scores (ES 0.149). Conclusion: This is the first study to identify demographic, injury, and psychosocial factors associated with hallucinogen use among individuals with SCI and to explore its relation to depression and QOL. These findings provide a foundation for future, fully powered studies aimed at determining the effect of hallucinogen use in the SCI population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.